Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Study to Compare the Safety and Efficacy of Tazarotene Lotion to Tazorac® (Tazarotene) Cream, in the Treatment of Acne Vulgaris

Trial Profile

A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Study to Compare the Safety and Efficacy of Tazarotene Lotion to Tazorac® (Tazarotene) Cream, in the Treatment of Acne Vulgaris

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tazarotene (Primary) ; Tazarotene
  • Indications Acne vulgaris
  • Focus Therapeutic Use
  • Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
  • Most Recent Events

    • 01 Jun 2022 Results assessing the dermal sensitization, safety, tolerability, and participant satisfaction data from five phase-1, -2, and -3 studies ( (phase-2 (NCT02938494) and two phase-3 studies (NCT03168334; NCT03168321))) of lower-dose tazarotene 0.045% polymeric emulsion lotion were published in the Journal of Dermatological Treatment.
    • 23 Jun 2020 According to a Bausch Health Companies media release, Emil Tanghetti is the lead investigator of the study.
    • 23 Jun 2020 Results published in the Bausch Health Companies Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top